Ibex Medical Analytics vs Mindpeak (2026)
Ibex sells cancer detection with a US clearance; Mindpeak sells biomarker scoring with European marks. Ibex's Galen Second Read is 510(k) cleared (K241232) for prostate biopsies initially called benign, and its breast and gastric solutions are CE-IVD marked elsewhere and research use only in the United States. Mindpeak lists 11 CE-IVD products for breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and has no FDA clearance.
- You want an FDA clearance that covers the AI itself, on prostate biopsies.
- Results should return into the image management and laboratory systems you already run.
- Your security review wants the business associate addendum and subprocessor list published.
- Biomarker scoring on immunohistochemistry, such as HER2, ER, PR, Ki-67 or PD-L1, is your need.
- You already run PathAI's AISight, which distributes Mindpeak's algorithms.
- Multiplex immunofluorescence quantification matters to your research.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ibex Medical Analytics and Mindpeak are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ibex Medical Analytics | Mindpeak |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2018 |
| Headquarters | Tel Aviv, Israel | Hamburg, Germany |
| Website | ibex-ai.com | mindpeak.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cancer diagnostics company selling Galen, AI applications that analyze H&E whole slide images for prostate, breast and gastric cancer and return results into laboratories' existing image management and laboratory systems through partners including Roche, Philips, Proscia and Sectra.
Source: AI Health Index, September 2026
Hamburg based computational pathology company, with a US entity in Cambridge, Massachusetts, focused on biomarker quantification from H&E, immunohistochemistry and multiplex immunofluorescence images. It lists 11 CE-IVD products, covering breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and states that its other products are research use only; it has no FDA clearance.
Source: AI Health Index, September 2026
Questions buyers ask
How do Ibex Medical Analytics and Mindpeak work with the EHR?
For Ibex Medical Analytics, the 510(k) summary describes the cleared product ingesting slides automatically from the scanner and image management system, with the diagnosis documented in another system such as the LIS.
With Mindpeak, the algorithm reaches the pathologist through someone else's product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Ibex Medical Analytics and Mindpeak handle patient data?
The Data Protection Addendum (last updated February 2026), linked from the trust center, lets Ibex delete customer personal data 21 days after receipt unless a different period is agreed in the purchase confirmation, and requires deletion from Ibex's and its sub-processors' systems at termination or on written request.
For Mindpeak, the customer must warrant that it owns the necessary rights and has obtained all applicable consents. The upload policy page is marked noindex, so search engines do not surface it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Ibex Medical Analytics and Mindpeak?
With Ibex Medical Analytics, the Galen Second Read 510(k) summary (K241232) reports a standalone study on 347 benign-diagnosed cases at three sites and a reader study on 772 cases (396 with cancer, 376 benign) read by 12 pathologists at four sites, three in the United States, each case read with and without the device after a two week washout.
In Mindpeak's case, a study by Abele and colleagues assessed the Breast Ki-67 and ER/PR products for quantifying Ki-67, ER, and PR, finding reliability across a wide range of image variance and pathologist confirmation, and concluding the tools can improve interobserver agreement in real world clinical settings. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Ibex Medical Analytics and Mindpeak leave to the clinician?
For Ibex Medical Analytics, the Galen Second Read 510(k) summary (K241232) states that the device runs only on cases the pathologist has already diagnosed as benign. It first measures the amount of tissue and of out-of-focus tissue on each slide and scores only slides within predetermined ranges; slides whose score crosses a predetermined threshold get a case- and slide-level alert with a heatmap, and slides below it get no output.
Mindpeak ships both region of interest products, where the pathologist selects the area analyzed, and whole slide analysis. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Mindpeak's general terms grant it a perpetual, sublicensable right to use analyzed images, including to retrain its AI. Ibex publishes its business associate addendum. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.